Standard BioTools (LAB)
Sells retained mass-cytometry and microfluidic genomics systems after the SomaScan sale.
Something off on this page? Send us feedback.
Provides CyTOF and Hyperion mass-cytometry platforms, Biomark X9 microfluidic genomics systems, related consumables, software and services. Continuing operations are concentrated in retained life-science tools after the SomaScan sale, while the pending Treeline merger could change the listed company's identity if it closes.
Operates as a life-science-tools supplier focused on retained mass cytometry and microfluidic genomics. Current lines include CyTOF XT and CyTOF XT PRO for high-parameter single-cell analysis, Hyperion XTi for imaging mass cytometry, Biomark X9 for PCR, qPCR and NGS library-prep workflows, plus Maxpar, IMC and Advanta consumables.
Revenue comes from instruments, consumables and services, with consumables tied to active instrument use. Operations are global, but the employee base is mostly outside the United States, and manufacturing is concentrated in Singapore for microfluidics and Canada for mass-cytometry instruments and reagents.
The business excludes SomaScan after the Illumina sale. Products are sold for research use only, and the pending Treeline merger could shift the listed security from life-science tools to a Treeline-led drug-development company if it closes.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 27, 2025 | Keybanc | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $476.7M · Total debt $28.1M · Total assets $627.2M · Shareholders' equity $540.0M
- Revenue
- $20.1M
- Operating income
- −$25.4M
- Net income
- −$26.8M
No dividends on record.
| Institutions | 75.88% | 297.88M shares | |
|---|---|---|---|
| 149 holders · as of Jun 30, 2026 | |||
| Insiders | 26.30% | 103.27M shares | |
| 8 holders · as of Aug 24, 2026 | |||
| Strategic holders | 18.37% | 72.10M shares | |
| 1 holder · as of Dec 4, 2025 | |||
| Adds to | 120.55% | ||
392.58M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 120.55%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Eli Casdin1Insiderdirector, 10 percent owner | 23.93% | 93.85M | filed Jun 23, 2026 |
Casdin Capital, LLCInstitution | 22.62% | 88.78M | as of Jun 30, 2026 |
Casdin Partners Master Fund, L.P.2Strategicdirector, 10 percent owner | 18.37% | 72.10M | filed Dec 4, 2025 |
Viking Global Investors LPInstitution | 14.94% | 58.65M | as of Jun 30, 2026 |
Mak Capital One LLCInstitution | 7.34% | 28.81M | as of Jun 30, 2026 |
- Eli Casdin's transaction reports restate only vehicles that traded; the 2026 ownership statement (93.85M) plus the 99.1K net shares acquired since is used instead.
- Casdin Partners Master Fund, L.P. reports a block also reported by Morgan Stanley; it is counted once, under Morgan Stanley.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 2, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +125,000 | $1.42 |
| Dec 3, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +75,000 | $1.44 |
| Dec 4, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +150,000 | $1.45 |
| Nov 24, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +150,000 | $1.43 |
| Nov 25, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +7,550,000 | $1.30 |
- Thermo Fisher Scientific
Broad life-science tools overlap across cytometry, qPCR and services
- BD
Direct flow-cytometry substitute for high-parameter cell analysis
- Cytek
Pure-play spectral flow cytometry challenger to CyTOF
- Bio-Rad Laboratories
PCR and digital-PCR rival for Biomark genomics workflows
- 10x Genomics
Single-cell and spatial biology platform budget competitor
- Bruker
Spatial-biology and proteomics rival through NanoString assets
- Agilent Technologies
Genomics, cell-analysis and lab-workflow competitor
- Mesa Laboratories
Agena genomics niche competitor under a Nasdaq parent
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Standard BioTools | $0.7504 | +1.15% | $290.4M | — | — | 3.4 | −7.6% |
| Thermo Fisher Scientific | $658.84 | +0.01% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| BD | $183.46 | +1.53% | $49.79B | 54.4 | 13.9 | 2.4 | −9.6% |
| Cytek | $5.67 | +7.39% | $681.9M | — | — | 3.3 | +5.6% |
| Bio-Rad Laboratories | $381.52 | +1.11% | $10.16B | 45.7 | 37.0 | 3.9 | −0.1% |
| 10x Genomics | $80.53 | +1.81% | $10.04B | — | — | 16.3 | −12.7% |
| Bruker | $61.30 | −0.45% | $9.37B | — | 27.1 | 2.7 | +5.2% |
| Agilent Technologies | $166.63 | +2.90% | $45.75B | 31.9 | 25.4 | 6.2 | +8.1% |
| Mesa Laboratories | $135.90 | +3.06% | $737.9M | 157.0 | 16.5 | 3.0 | +1.0% |
| Median | 45.7 | 25.3 | 3.6 | +3.1% |